Novo Bets On ‘Chequered’ CB1r Approach In Diabetic Kidney Disease With Inversago Buy
For Up To $1.08bn
The Danish firm’s Q2 sales fell short of expectations due to poor rare disease and diabetes performance, but a potentially billion-dollar buy of Inversago stole attention as observers highlighted the historical risks of targeting the cannabinoid-1 receptor.
